Summary - Funding Rounds

Founding Date

2008

Total Funding

$248.7 m

Investors

Karyopharm Therapeutics is a subsidiary of Biogen

Karyopharm Therapeutics Income Statement

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

171.0k21.0k21.0k150.0k75.0k59.0k48.0k68.0k19.9m239.0k155.0k9.5m13.1m18.1m33.5m21.3m23.3m

Cost of goods sold

1.0m

Gross profit

12.1m

Gross profit Margin, %

92%

R&D expense

7.7m11.0m13.2m16.0m20.8m27.0m25.9m21.8m24.6m19.9m24.1m23.1m25.2m41.3m44.7m36.4m38.0m26.5m26.3m34.0m42.6m37.0m37.1m

General and administrative expense

1.6m2.9m3.3m3.8m5.4m6.2m4.8m5.6m6.0m5.9m6.3m6.6m5.8m7.6m9.5m13.0m27.1m24.7m25.3m30.7m30.8m31.0m37.7m

Operating expense total

9.3m13.9m16.5m19.8m26.2m33.2m30.7m27.3m30.5m25.8m30.3m29.8m31.1m48.9m54.2m49.4m65.1m51.2m51.5m64.7m73.4m68.0m74.7m

EBIT

(9.3m)(13.7m)(16.4m)(19.7m)(26.1m)(33.0m)(30.6m)(27.3m)(30.5m)(25.7m)(30.3m)(29.8m)(31.1m)(38.9m)(34.3m)(49.2m)(64.9m)(41.7m)(39.4m)(47.4m)(40.3m)(47.1m)(52.4m)

EBIT margin, %

(8019%)(78324%)(94019%)(22009%)(40813%)(51654%)(53629%)(44528%)(173%)(20567%)(41885%)(439%)(300%)(261%)(120%)(221%)(225%)

Interest expense

18.0k17.0k20.0k237.0k290.0k318.0k317.0k385.0k383.0k428.0k495.0k660.0k1.1m1.2m1.7m1.9m

Interest income

141.0k267.0k239.0k286.0k329.0k311.0k400.0k412.0k454.0k509.0k653.0k1.1m1.8m1.4m1.1m975.0k849.0k600.0k264.0k

Pre tax profit

(29.9m)(29.4m)(30.6m)(38.4m)(33.7m)(48.1m)(66.2m)(43.4m)(41.3m)(52.9m)(46.3m)(53.5m)(57.3m)

Income tax expense

23.0k18.0k13.0k12.0k(17.0k)14.0k10.0k8.0k20.0k66.0k137.0k44.0k149.0k

Net Income

(9.3m)(13.7m)(16.4m)(19.7m)(26.1m)(32.7m)(30.4m)(27.1m)(30.2m)(25.4m)(29.9m)(29.4m)(30.6m)(38.5m)(33.7m)(48.1m)(66.2m)(43.4m)(41.4m)(52.9m)(46.4m)(53.5m)(57.4m)

Karyopharm Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

156.0m150.6m58.4m49.7m69.0m118.0m128.9m85.9m

Accounts Receivable

7.9m

Prepaid Expenses

2.0m2.0m2.0m1.8m6.4m7.3m9.3m

Inventories

2.1m346.0k2.6m

Current Assets

158.0m207.8m177.6m131.6m148.4m334.6m278.6m276.5m

PP&E

240.0k2.8m3.5m2.8m2.2m3.9m3.0m2.2m

Total Assets

158.2m220.3m215.4m180.4m180.3m341.2m295.0m313.1m

Accounts Payable

1.7m6.3m3.8m4.8m5.7m4.3m985.0k4.5m

Short-term debt

1.9m

Current Liabilities

3.3m12.3m15.1m16.5m49.5m46.9m46.4m60.2m

Long-term debt

13.2m142.4m

Total Debt

13.2m144.3m

Total Liabilities

13.5m17.1m18.1m50.8m158.0m245.2m262.5m

Common Stock

3.0k3.0k4.0k5.0k6.0k7.0k7.0k

Additional Paid-in Capital

217.5m345.2m455.2m528.6m625.0m857.2m923.1m1.1b

Retained Earnings

(138.3m)(256.5m)(366.1m)(495.3m)(673.7m)(873.3m)(1.1b)

Total Equity

154.9m206.8m198.4m162.2m129.5m183.2m49.8m50.5m

Financial Leverage

1 x1.1 x1.1 x1.1 x1.4 x1.9 x5.9 x6.2 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

52.9m144.9m132.3m227.1m51.5m24.2m43.5m42.2m37.7m43.9m25.6m55.4m54.5m37.5m119.0m101.6m83.5m75.5m168.0m202.2m103.1m82.3m

Accounts Receivable

7.9m9.3m9.6m

Prepaid Expenses

658.0k2.7m3.0m4.2m2.9m4.1m3.1m1.7m1.5m3.4m2.1m2.1m2.1m2.4m3.4m4.8m7.0m5.7m5.3m7.6m8.0m8.2m

Inventories

100.0k970.0k1.7m2.0m

Current Assets

53.6m147.6m135.3m231.3m249.3m225.3m198.3m138.1m124.2m130.3m112.2m145.7m121.7m133.3m244.6m211.6m271.4m222.8m280.9m370.9m317.8m285.4m

PP&E

246.0k322.0k604.0k2.7m3.3m3.2m3.7m3.3m3.2m3.0m2.7m2.5m2.3m2.5m2.6m2.9m3.6m3.4m3.2m2.8m2.6m2.4m

Total Assets

55.9m149.3m137.7m235.2m292.0m263.3m237.0m192.1m170.9m183.6m155.4m185.8m163.8m146.4m256.6m220.0m287.2m238.1m297.7m416.1m380.0m337.6m

Accounts Payable

1.7m3.3m3.5m2.1m7.0m4.5m4.6m4.1m4.1m2.2m4.2m3.2m1.9m4.9m3.8m2.2m2.3m1.1m3.1m1.7m1.9m2.4m

Short-term debt

1.7m1.8m1.8m

Current Liabilities

4.0m5.0m5.6m6.2m14.7m14.1m14.4m13.2m15.5m15.0m15.5m17.5m21.2m46.7m36.5m41.6m43.9m32.2m39.2m49.7m50.6m52.6m

Long-term debt

14.5m14.1m13.6m124.5m126.1m127.6m

Total Debt

14.5m14.1m13.6m126.2m127.8m129.4m

Total Liabilities

6.0m7.4m16.5m16.0m16.4m15.1m17.3m16.7m17.1m19.0m22.6m50.8m43.1m48.9m165.9m155.6m237.9m250.0m250.2m253.8m

Common Stock

2.6m3.0k3.0k3.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k5.0k5.0k5.0k6.0k6.0k6.0k6.0k6.0k7.0k7.0k7.0k

Additional Paid-in Capital

2.6m220.4m224.4m340.2m439.9m444.6m448.1m460.5m467.2m506.1m534.8m592.5m597.6m629.6m781.2m786.8m861.2m865.7m884.6m1.1b1.1b1.1b

Retained Earnings

(164.4m)(197.1m)(227.5m)(283.6m)(313.7m)(339.2m)(396.3m)(425.7m)(456.3m)(533.8m)(567.5m)(615.5m)(739.9m)(783.3m)(824.7m)(926.3m)(972.7m)(1.0b)

Total Equity

(47.8m)144.1m131.7m227.8m275.5m247.3m220.6m177.0m153.6m166.9m138.4m166.7m141.2m95.5m213.5m171.1m121.3m82.5m59.9m166.1m129.8m83.8m301.0k

Financial Leverage

-1.2 x1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.5 x1.2 x1.3 x2.4 x2.9 x5 x2.5 x2.9 x4 x

Karyopharm Therapeutics Cash Flow

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(21.8m)(13.7m)(30.1m)(49.8m)(26.1m)(58.8m)(89.1m)(27.1m)(57.2m)(82.6m)(29.9m)(59.3m)(89.9m)(38.5m)(72.1m)(120.2m)(66.2m)(109.6m)(150.9m)(52.9m)(99.4m)(152.9m)(57.4m)

Depreciation and Amortization

106.0k43.0k85.0k191.0k136.0k292.0k457.0k179.0k358.0k537.0k183.0k363.0k539.0k169.0k353.0k541.0k245.0k487.0k730.0k242.0k480.0k715.0k235.0k

Accounts Receivable

(7.9m)(1.4m)(1.7m)(3.2m)(5.0m)

Inventories

(100.0k)(624.0k)(1.3m)(1.7m)(552.0k)

Accounts Payable

673.0k1.5m1.7m362.0k268.0k(1.8m)(2.1m)294.0k233.0k(1.7m)(522.0k)(1.5m)(2.9m)(773.0k)(1.9m)(3.4m)(2.0m)(3.2m)(1.2m)711.0k903.0k1.4m(1.4m)

Cash From Operating Activities

(20.2m)(10.6m)(22.5m)(38.7m)(20.2m)(48.3m)(73.7m)(23.2m)(44.1m)(64.4m)(24.7m)(46.4m)(68.2m)(34.7m)(72.3m)(110.9m)(66.6m)(114.8m)(151.3m)(45.0m)(85.3m)(129.6m)(52.9m)

Purchases of PP&E

(25.0k)(125.0k)(449.0k)(2.7m)(178.0k)(774.0k)(911.0k)(39.0k)(45.0k)(45.0k)(7.0k)(382.0k)(779.0k)(1.3m)(49.0k)(49.0k)(156.0k)(10.0k)(26.0k)(26.0k)

Cash From Investing Activities

(25.0k)(525.0k)(849.0k)(3.1m)(170.1m)(169.2m)(124.7m)6.8m23.0m18.0m549.0k(585.0k)20.0m2.5m(25.1m)(4.6m)32.0m71.8m112.0m(46.5m)(106.5m)(85.1m)43.2m

Cash From Financing Activities

72.8m13.0k(367.0k)113.0m91.2m91.2m91.2m196.0k436.0k31.9m57.0k52.6m52.8m429.0k147.6m148.3m152.0k547.0k89.4m164.8m166.9m168.1m10.7m

Net Change in Cash

52.5m(11.1m)(23.7m)71.2m(99.2m)(126.4m)(107.1m)(16.2m)(20.6m)(14.4m)(24.1m)5.7m4.8m(31.7m)50.1m32.8m(34.5m)(42.5m)50.0m73.3m(25.0m)(46.6m)883.0k

Karyopharm Therapeutics Ratios

USDQ3, 2013

Financial Leverage

-1.2 x

Karyopharm Therapeutics Operating Metrics

FY, 2015

Patents Issued

10

Karyopharm Therapeutics Employee Rating

3.976 votes
Culture & Values
3.8
Work/Life Balance
3.4
Senior Management
3.7
Salary & Benefits
4.1
Career Opportunities
3.9
Source